Research view
Switch to patient viewColorectal cancer: trials that stopped early
Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Reason given in the registry “Business reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2025.
- Ended
- Jan 2024
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04000529
Terminated
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer
Reason given in the registry “Slow enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2025.
- Ended
- Nov 2024
- Run by
- Washington University School of Medicine
- Registry record
- NCT04827732
Terminated
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
Reason given in the registry “the study recruitment is significantly behind expectations as only one single patient has started treatment”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2025.
- Ended
- Jan 2024
- Phase
- Phase 2
- Run by
- Enterome
- Registry record
- NCT05350501
Suspended
Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening
Reason given in the registry “fundraising”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Sept 2025.
- Run by
- Metabiomics Corp
- Registry record
- NCT04693546
Terminated
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Reason given in the registry “Limited resources and strategic priorities”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2025.
- Ended
- Sept 2025
- Phase
- Phase 1
- Run by
- Ikena Oncology
- Registry record
- NCT06270082
Terminated
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Reason given in the registry “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Sept 2025.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT06285097
Terminated
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Sept 2025.
- Ended
- Feb 2025
- Phase
- Phase 1/2
- Run by
- Bolt Biotherapeutics, Inc.
- Registry record
- NCT04278144
Terminated
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
Reason given in the registry “A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Sept 2025.
- Ended
- Aug 2024
- Phase
- Phase 2
- Run by
- NuCana plc
- Registry record
- NCT05678257
Withdrawn
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Reason given in the registry “PI left NIH.”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Sept 2025.
- Ended
- Sept 2025
- Phase
- Phase 2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT06690281
Withdrawn
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Reason given in the registry “PI left NIH.”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Sept 2025.
- Ended
- Sept 2025
- Phase
- Phase 2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT06410534
Terminated
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Reason given in the registry “This was a strategic business decision. There were no safety concerns contributing to this decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2025.
- Ended
- Sept 2024
- Phase
- Phase 1
- Run by
- Incyte Corporation
- Registry record
- NCT04989387
Withdrawn
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Reason given in the registry “Discontinuation of molecule development”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2025.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- Institut Bergonié
- Registry record
- NCT06084689
Terminated
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Reason given in the registry “Low accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Aug 2025.
- Ended
- Dec 2023
- Run by
- Academic and Community Cancer Research United
- Registry record
- NCT03765736
Withdrawn
Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2)
Reason given in the registry “The ICCAUT-1 trial failed to demonstrate the superiority of the ICCAUT strategy in urinary dysfunction. Therefore, there is no need to conduct subsequent trials.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Aug 2025.
- Run by
- The First Hospital of Jilin University
- Registry record
- NCT06217016
Terminated
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Reason given in the registry “Sponsor reprioritization of active trials.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2025.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- 3B Pharmaceuticals GmbH
- Registry record
- NCT05605522
Terminated
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Aug 2025.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- Day One Biopharmaceuticals, Inc.
- Registry record
- NCT07121829
Terminated
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
Reason given in the registry “Study terminated due to change in therapeutic landscape.”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Aug 2025.
- Ended
- Jul 2025
- Phase
- Phase 1
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Registry record
- NCT05743036
Suspended
Endorectal Brachytherapy for Rectal Cancer
Reason given in the registry “Unknown time frame for availability of new endorectal probes”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Aug 2025.
- Phase
- Phase 2
- Run by
- University Hospital, Bordeaux
- Registry record
- NCT05591534
Terminated
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Reason given in the registry “Due to lack of efficacy shown at the time of the interim analysis.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Jul 2025.
- Ended
- Jun 2024
- Phase
- Phase 2
- Run by
- SOTIO Biotech AG
- Registry record
- NCT05619172
Terminated
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
Reason given in the registry “Drugs Unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Jul 2025.
- Ended
- Mar 2024
- Phase
- Phase 2
- Run by
- Patrick Boland
- Registry record
- NCT03547999
Terminated
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Reason given in the registry “At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.
- Ended
- Jun 2024
- Phase
- Phase 1/2
- Run by
- Hutchmed
- Registry record
- NCT04577963
Terminated
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Reason given in the registry “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2025.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Registry record
- NCT05563272
Terminated
SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study
Reason given in the registry “Voluntary and temporary suspension of enrollment.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.
- Ended
- Jan 2024
- Run by
- SafeHeal Inc
- Registry record
- NCT05010850
Terminated
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
Reason given in the registry “slow accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.
- Ended
- Mar 2024
- Phase
- Phase 2
- Run by
- University of Florida
- Registry record
- NCT04786600
Terminated
A Study to Investigate LYL845 in Adults With Solid Tumors
Reason given in the registry “Pipeline Reprioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Jul 2025.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- Lyell Immunopharma, Inc.
- Registry record
- NCT05573035
Suspended
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2025.
- Ended
- Sept 2025
- Phase
- Phase 1
- Run by
- NextPoint Therapeutics, Inc.
- Registry record
- NCT05958199
Withdrawn
TCR1020-CD8 T Cells in KRAS-mutated Cancers
Reason given in the registry “Administrative decision”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2025.
- Phase
- Phase 1
- Run by
- University of Pennsylvania
- Registry record
- NCT06707896
Terminated
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2025.
- Ended
- Oct 2024
- Phase
- Phase 1
- Run by
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Registry record
- NCT05432193
Terminated
Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis
Reason given in the registry “Need for device upgrade.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Jun 2025.
- Ended
- Sept 2024
- Run by
- Weill Medical College of Cornell University
- Registry record
- NCT04964297
Withdrawn
A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer
Reason given in the registry “Company shifted focus”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2025.
- Run by
- ProgenaBiome
- Registry record
- NCT04148378
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.